LILRB1 Blockade Enhances Bispecific T Cell Engager Antibody–Induced Tumor Cell Killing by Effector CD8+ T Cells

Elicitation of tumor cell killing by CD8+ T cells is an effective therapeutic approach for cancer. In addition to using immune checkpoint blockade to reinvigorate existing but unresponsive tumor-specific T cells, alternative therapeutic approaches have been developed, including stimulation of polycl...

Full description

Bibliographic Details

Published in:	The Journal of immunology (1950) 2019-08, Vol.203 (4), p.1076-1087
Main Authors:	Kim, Aeryon, Han, Chia-Jung, Driver, Ian, Olow, Aleksandra, Sewell, Andrew K, Zhang, Zemin, Ouyang, Wenjun, Egen, Jackson G, Yu, Xin
Format:	Article
Language:	English
Subjects:	Antibodies, Bispecific - immunology Antibodies, Bispecific - pharmacology Antigens, CD - immunology Humans Immunotherapy - methods Leukocyte Immunoglobulin-like Receptor B1 - antagonists & inhibitors Leukocyte Immunoglobulin-like Receptor B1 - immunology Lymphocyte Activation - drug effects Lymphocyte Activation - immunology Neoplasms - immunology T-Lymphocyte Subsets - immunology T-Lymphocytes, Cytotoxic - immunology Tumor Cells, Cultured Tumor Immunology
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!